


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of Plowman *et al.*

Appl. No.: 10/532,432

Filing Date: April 22, 2005

For: MAP2K6 AS MODIFIER OF
BRANCHING MORPHOGENESIS
AND METHODS OF USE



Confirmation No.: 4479

Art Unit: to be assigned

Examiner: to be assigned

Attorney Docket No.: EX03-078C-US

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 CFR §1.56, this Information Disclosure Statement is being submitted for the above-referenced application.

Applicant requests the Office to consider this Information Disclosure Statement under 37 C.F.R. §1.97 (b)(2) and states that the information contained in the attached PTO Form 1449 was first cited in the International Search Report (copy attached) from the International Searching Authority in the counterpart PCT application, PCT/US2003/33489.

In accordance with §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined by 37 CFR §1.56 exists.

In accordance with §1.97(h), the disclosure contained herein is not intended to constitute an admission that any patent, publication, or other information referred to is "prior art" or "analogous art" for this invention.

It is believed that no fees are required, as the disclosure is submitted before the first Office Action. However, in the event that fees are due, the Commissioner is authorized to charge any required fees, to deposit account no. 50-1108.

Dated: 7/31/06
Exelixis, Inc.
170 Harbor Way, P.O. Box 511
South San Francisco, CA 94083-0511

Respectfully submitted,


Peter K. Seperack, Reg. No. 47,932

Tel: (650) 837-7284; Fax: (650) 837-8234

AUG 02 2006

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1 of 1

Complete if Known

Application Number	10/532,432
Filing Date	April 22, 2005
First Named Inventor	Plowman et al.
Art Unit	to be assigned
Examiner Name	to be assigned

Attorney Docket Number

EX03-078C-US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	A-1	US-6,033,910	03-07-2000	Monia	
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	B-1	Database Medline on STN, ACS (Columbus, OH, USA), Accession No. 2001489213, WONG et al., "Profiling of protein kinases in the neoplastic transformation of human ovarian surface epithelium", Gynecologic Oncology, vol. 82, pages 305-311, (2001).	
	B-2	LUO et al., "Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling", Cancer Research, vol. 15, pages 4683-4688, (2001).	
	B-3	KOOCHEKPOUR et al., "The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells", Molecular and Cellular Biology, vol. 19 (9), pages 5902-5912, (1999).	
	B-4	SALVUCCI ET AL., "Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1", Blood, vol. 99 (8), pages 2703-2707, (2002).	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.